The sharp revenue acceleration, especially in Q4, combined with the Corstasis acquisition and narrowing losses, suggests improving fundamentals and strategic expansion. Traders should monitor U.S. prescription growth trends, integration of Enbumyst™, and progress on triple-combination therapies expected in 2027.
Price Chart
Executive Summary
Esperion Therapeutics reported strong financial results for Q4 and full-year 2025, with total revenue growing 144% YoY in Q4 to $168.4 million and 21% for the full year to $403.1 million. U.S. net product revenue grew 38% YoY in both periods, driven by bempedoic acid franchise momentum. The company also announced an acquisition of Corstasis Therapeutics to expand its cardiovascular portfolio with Enbumyst™, a nasal spray diuretic for heart failure patients.
Key Financial Metrics
Key Facts
- Q4 2025 total revenue grew 144% YoY to $168.4 million; full-year 2025 revenue grew 21% to $403.1 million
- Q4 U.S. net product revenue grew ~38% YoY to $43.7 million; full-year U.S. net product revenue grew 38% to $159.6 million
- Q4 retail prescription equivalents grew 34% YoY and 11.3% Q/Q
- Net income of $61.8 million in Q4 2025 vs. net loss of $21.3 million in Q4 2024
- Full-year 2025 net loss narrowed to $22.7 million from $51.7 million in 2024
- Acquired Corstasis Therapeutics to add Enbumyst™, a first-in-class nasal spray diuretic for CHF, hepatic, and renal edema
- Cash and cash equivalents increased to $167.9 million from $144.8 million in 2024
- Otsuka partnership in Japan triggered a $90 million payment to Esperion
Financial Impact
Q4 revenue more than doubled YoY with $168.4M vs. $69.1M; full-year revenue up $70.8M YoY. Net loss cut by over 56% despite R&D and SG&A increases. $90M one-time payment from Japan significantly boosted collaboration revenue.
Risk Factors
- Future profitability depends on sustaining U.S. prescription growth and payer coverage
- Integration risk from Corstasis acquisition and execution on new pipeline candidates
- Dependence on international partners for royalty revenue; fluctuations possible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252553 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access